Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Low-Dose Aspirin Use & Endometrial Cancer Outcomes

Obstet Gynecol; ePub 2016 Jun 6; Matsuo, Cahoon, et al

Low-dose aspirin use is associated with improved survival outcomes in women with endometrial cancer, especially in those who are young, obese, with low-grade disease, and who receive postoperative radiotherapy. This according to a multicenter, retrospective study of 1,687 women with stage I-IV endometrial cancer who underwent hysterectomy-based surgical staging between January 2000 and December 2013. 158 (9.4%) patients were taking low-dose aspirin and median follow-up time was 31.5 months. Researchers found:

• 127 (7.5%) patients died of endometrial cancer.

• Low-dose aspirin use was significantly correlated with concurrent obesity, hypertension, diabetes mellitus, and hypercholesterolemia.

• Low-dose aspirin was not associated with histologic subtype, tumor grade, nodal metastasis, or cancer stage.

• Low-dose aspirin use remained an independent prognostic factor associated with an improved 5-year disease-free survival rate (90.6% vs 80.9%; aHR, 0.46) and disease-specific overall survival rate (96.4% vs 87.3%; aHR, 0.23).

• The increased survival rate was greatest in patients aged <60 years, with body mass index ≥30, who had type I cancer, and who received postoperative whole pelvic radiotherapy.

Citation: Matsuo K, Cahoon SS, Yoshihara K, et al. Association of low-dose aspirin and survival of women with endometrial cancer. [Published online ahead of print June 6, 2016]. Obstet Gynecol. doi:10.1097/AOG.0000000000001491.